**Technology Advisory Committee B Interests Register**

**Siponimod for treating secondary progressive multiple sclerosis [ID1304]**

**Publication Date: 18/11/2020**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Name | Role with NICE | Type of interest | Description of interest | Interestarose | Interestdeclared | Interest ceased | Comments |
| Dr Matt Craner   | Clinical Expert | Direct - financial | Undertaken speaker duties and has provided educational courses for the following pharmaceutical companies: Teva, Roche, Novartis, Biogen, and Merck. | NA | 12/09/2019 | NA | It was agreed that this declaration would not prevent Dr Craner from participating in this section of the meeting. |
| Dr Matt Craner   | Clinical Expert | Direct – non-financial | Advised MS Society and MS Trust on matters related to care of patients with MS and disease modifying therapies. | NA | 12/09/2019 | NA | It was agreed that this declaration would not prevent Dr Craner from participating in this section of the meeting. |
| Dr Matt Craner   | Clinical Expert | Indirect interest  | Employed by the MoD as a consultant neurologist delivering care to military personnel with neurological conditions | NA | 12/09/2019 | NA | It was agreed that this declaration would not prevent Dr Craner from participating in this section of the meeting. |
| Mrs Jacqueline Krarup | Patient Expert | Direct – non-financial | Invited by Novartis to give a presentation on her experience of multiple sclerosis. | NA | 12/03/2020 | NA | It was agreed that this declaration would not prevent Mrs Krarup from participating in this section of the meeting. |
| Mrs Carmel Wilkinson | Clinical Expert | Direct - financial | Worked with Novartis on a project regarding Siponimod and ‘Benefits treatment landscapes’ | NA | 12/03/2020 | NA | It was agreed that this declaration would not prevent Mrs Wilkinson from participating in this section of the meeting. |